ArticleMolecules (Basel, Switzerland)2008
Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action.
Article in Molecules (Basel, Switzerland), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 161 citations in OpenAlex.
- Trial
- Guanidine-Based Ligands in Bioinorganic Chemistry: Coordination Modes and Applications in Anticancer Metallodrugs.Bioinorganic chemistry and applications · 2026Review
- Hybrid Molecules as Efficient Drugs against Multidrug-Resistant Malaria Parasites.ChemMedChem · 2025Review
- Recent advances, challenges and updates on the development of therapeutics for malaria.EXCLI journal · 2024Review
- Quinoline as a Privileged Structure: A Recent Update on Synthesis and Biological Activities.Current topics in medicinal chemistry · 2024Review
- Investigations on the Novel Antimalarial Ferroquine in Biomimetic Solutions Using Deep UV Resonance Raman Spectroscopy and Density Functional Theory.Analytical chemistry · 2023Article
- A Molecular Electron Density Theory Study of the [3+2] Cycloaddition Reaction of an Azomethine Ylide with an Electrophilic Ethylene Linked to Triazole and Ferrocene Units.Molecules (Basel, Switzerland) · 2022Article
- Harmicens, Novel Harmine and Ferrocene Hybrids: Design, Synthesis and Biological Activity.International journal of molecular sciences · 2022Article
- Synthesis and Structure Elucidation of Novel Spirooxindole Linked to Ferrocene and Triazole SystemsMolecules (Basel, Switzerland) · 2022Article
- Facing Diseases Caused by Trypanosomatid Parasites: Rational Design of Pd and Pt Complexes With Bioactive Ligands.Frontiers in chemistry · 2021Review
- Recent Advances in the Biological Investigation of Organometallic Platinum-Group Metal (Ir, Ru, Rh, Os, Pd, Pt) Complexes as Antimalarial Agents.Molecules (Basel, Switzerland) · 2020Review
- Metallodrugs are unique: opportunities and challenges of discovery and development.Chemical science · 2020Review
- Article
- Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery.Cell chemical biology · 2020Article
- Ferrocene-Based Compounds with Antimalaria/Anticancer Activity.Molecules (Basel, Switzerland) · 2019Review
- Synthesis, characterization and biological activity of organometallic derivatives of the antimalarial drug mefloquine as new antischistosomal drug candidates.MedChemComm · 2018Article
- Ferroquine, the next generation antimalarial drug, has antitumor activity.Scientific reports · 2017Article
- Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.Iranian journal of medical sciences · 2017Review
- Ferrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells.ACS medicinal chemistry letters · 2016Article
- Ferroquine and its derivatives: new generation of antimalarial agents.European journal of medicinal chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the first organometallic drug: a ferrocenyl group covalently flanked by a 4-aminoquinoline and a basic alkylamine. FQ is able to overcome the CQ resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria. After fifteen years of effort, it is now possible to propose a multifactorial mechanism of action of FQ by its capacity to target lipids, to inhibit the formation of hemozoin and to generate reactive oxygen species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.